The Church of England's commissioners announced in January 2023 that they would spend £100m from their £11.6bn endowment to create the Fund for Healing, Repair and Justice — restitution for the church's direct involvement in the transatlantic slave trade. The historical basis is concrete: Queen Anne's Bounty invested in the South Sea Company, which trafficked roughly 34,000 enslaved Africans. Church of England clergymen financed the Royal African Company, which trafficked more Africans than any single organisation in the history of the trade. Grant Thornton forensic accountants traced the money. This is not speculative guilt. The campaign to kill Project Spire has been led by Lord Nigel Biggar, retired Oxford regius professor of moral theology, Conservative peer, and Anglican priest. Biggar has published dozens of articles across the Spectator, Daily Telegraph, Daily Mail, and the Times. He co-authored a 58-page Policy Exchange paper titled "The Case Against Reparations." He commissioned a Merlin Strategy poll of 500 churchgoers, and a press release distributed by Conservative MP Katie Lam highlighted the finding that 61% might withhold donations — while omitting the poll's other finding that 61% would maintain or increase contributions. Biggar declined to answer questions about the poll. Lam did not respond to repeated requests for comment. The infrastructure behind Biggar connects to one node: Sir Paul Marshall, multimillionaire co-founder of hedge fund Marshall Wace. Marshall bought the Spectator in 2024 for £100m. He co-owns GB News with the Dubai-based fund Legatum. He co-founded UnHerd in 2017 with former Times journalist Tim Montgomerie. Biggar has appeared across all three platforms — GB News interviews, Spectator articles, UnHerd commentary, and two episodes of Marshall's son Winston Marshall's YouTube show. The Critic, founded by hedge fund tycoon and Brexit backer Jeremy Hosking, ran seven articles critical of Project Spire, including by Biggar and Lam. None were supportive. The campaign has worked. The fund has been stalled well past its planned 2024 launch. The church acknowledged in July 2025 that it faces a legal challenge that could add years of delay. Lam coordinated a letter from 27 MPs and peers to incoming Archbishop Sarah Mullally accusing the church of "legally dubious vanity projects." The pattern is textbook: media saturation creates the appearance of widespread opposition, polling is commissioned and selectively released to manufacture evidence, parliamentary pressure applies institutional friction, and legal threats impose cost and delay. What makes this case structurally important is the degree of vertical integration. One financier owns or funds the media platforms that publish the criticism, the commentator who leads the campaign, the thinktank that produces the policy paper, and the lobbying groups connected to the parliamentary pressure. This is not a grassroots backlash. It is an industrialised influence operation with identifiable funding sources, coordinated messaging, and selective disclosure of evidence — deployed against an institution attempting to address a historically documented wrong. The church's position is that Project Spire money comes from the endowment, not from parish funds. The £100m represents less than 1% of the £11.6bn endowment. The historical research — including the newly digitised Register of British Slave Traders — establishes the factual basis for the fund's existence. The question is not whether the church profited from slavery; that is settled. The question is whether a coordinated campaign by wealthy interests can prevent institutional accountability indefinitely. The 20-year trajectory is clear: if this model succeeds, any institution attempting historical reparations faces the same playbook — media capture, selective polling, thinktank papers, parliamentary letters, and legal challenges. The cost of accountability becomes prohibitive. The beneficiaries are those who prefer the status quo. The costs fall on communities descended from those the institution harmed.
